Research and Clinical Trials

Title  
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Brief Description  
To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Breast - Female
Status  
OPEN
Start Date  
03/21/2016
IRB Number  
00014114
Principal Investigator  
Vallabhaneni, Geetha
Contact Name  
Jenna Scalesse

For More Information, Contact  Jenna  , Scalesse
Phone:  704-403-1520 Fax:    
Email:  Jenna.Gregory@carolinashealthcare.org
Address:100 Medical Park Drive Suite 110 Concord, 28025
Close